Overview

An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201)

Status:
Recruiting
Trial end date:
2022-02-15
Target enrollment:
Participant gender:
Summary
The purpose of this Phase IIa study is to evaluate the safety and tolerability of ALLN-346 in subjects with hyperuricemia.
Phase:
Phase 2
Details
Lead Sponsor:
Allena Pharmaceuticals
Treatments:
Rasburicase